Article
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2024
Jensen Jeffrey L, Bobek Olivia, Chan Irenaeus C C, Miller Brian C, Hillman David W, Heller Glenn, Druley Todd, Armstrong Andrew J, Morris Michael J, Milowsky Matthew I, Beltran Himisha, Bolton Kelly L, Coombs Catherine C
Abstract excerpt
PURPOSE: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (OS), predominantly through cardiovascular adverse events (CVAE). Because androgen receptor pathway inhibitors (ARPI) used in metastatic castration-resistant prostate cancer...
Topics
Join the communities discussing this publication.
